Cite
HARVARD Citation
Mease, P. et al. (n.d.). OP0309 Characterisation of clinical benefits in subjects classified as acr20 non-responders at week 104 of apremilast treatment: subanalysis of 3 long-term, phase iii trials. Annals of the rheumatic diseases. pp. 201-202. [Online].